Floated in London last November at 290p (FTSE-250). Company website www.hikma.com

Develops, manufactures and markets branded and non-branded generic pharmaceuticals, as well as in-licensed, patented pharmaceuticals
Geographic markets: USA, Europe and the Middle East & North Africa (MENA); sales in 34 countries. Headquartered in London with manufacturing facilities in the US, Jordan, Portugal, Italy and Saudi Arabia. See factsheet


Recent bullish upgrade from Merrill Lynch.

Got cash in the bank and generating more - which it intends to spend on acquisitions across North Africa and in Europe. Just announced a secondary listing on the new Dubai Index which will bring it to the attention of investors in the gulf states.

Recent bbullish broker coverage of this stock..

Hikma Pharmaceuticals PLC

FORECASTS
2008 2009

Date Rec Pre-tax () EPS (p) DPS (p) Pre-tax () EPS (p) DPS (p)

Panmure Gordon
04-02-09 BUY 39.52 15.62 5.30 69.70 28.05 6.29

Charles Stanley Securities [W]
15-04-08 ACCU 47.96 22.72 4.54 68.16 31.81 5.55

2008 2009
Pre-tax () EPS (p) DPS (p) Pre-tax () EPS (p) DPS (p)

Consensus 39.52 15.62 5.30 69.70 28.05 6.29
1 Month Change 0.00 0.00 0.00 0.00 0.00 0.00
3 Month Change 0.00 0.00 0.00 0.00 0.00 0.00

Notes to forecasts
(21 Jul 08) W flag refers to outlook


GROWTH
2007 (A) 2008 (E) 2009 (E)

Norm. EPS 11.17% -10.83% 79.58%
DPS 80.95% 39.92% 18.68%

INVESTMENT RATIOS
2007 (A) 2008 (E) 2009 (E)

EBITDA 56.89m 61.31m 90.44m
EBIT 45.22m m m
Dividend Yield 0.98% 1.37% 1.63%
Dividend Cover 4.62x 2.95x 4.46x
PER 22.05x 24.73x 13.77x
PEG 1.97f -2.28f 0.17f
Net Asset Value PS 46.53p p p

Half Yearly Report


http://www.moneyam.com/action/news/showArticle?id=4428081

Hikma Pharmaceuticals on target to grow revenue by 20%
StockMarketWire.com
Jordan-based Hikma Pharmaceuticals said it remains on track to deliver revenue growth of 20% for the full year after group revenue increased by 34.8% to $532.3m in the half-year to end-June, with organic revenue up 7.6%.

hikma said branded revenue growth of 24.6% reflects strong demand across its MENA markets, with organic growth of 12.8%. The Branded business remains on track for around 20% full year revenue growth, with gross and adjusted operating margins broadly in line with 2011. An excellent performance in global Injectables delivered 94% revenue growth, with organic revenue growth of 25.7%, and adjusted operating margin of 22%.

Generics revenue decreased by 27% to $55.8m, reflecting the impact of additional compliance work at the Eatontown facility and increased pricing pressure. Full year revenue guidance is revised to around $115m.

Profit attributable to shareholders was up 22% to $40.4m. On an adjusted basis, profit attributable to shareholders is up 12.9% to $46m.

Net cash flow from operating activities rose $27.9m to $47.1m, reflecting growth in profitability and an ongoing focus on working capital management.

The group increased the interim dividend to 6.0 cents per share, up from 5.5 cents for the first half of last year.

Said Darwazah, CEO, said: 'We have had a strong start to the year in our Branded and Injectables businesses. I am pleased with the growth we have achieved in our key MENA markets this year. Our global Injectables business continues to deliver extremely strong growth, as we benefit from our increased scale and continued investment in quality and products. In our Generics business, where operations have been disrupted by additional compliance work, we expect sales to gradually improve in the second half.

'Overall, the Group is performing well and the outlook is positive for the second half. I am pleased to be able to reiterate our Group guidance of around 20% revenue growth for the full year.'

UPDATE 1-Drugmaker Hikma estimates 23 percent full-year revenue growth

14 Feb 2014 - 09:32
(Adds details, analyst comments; updates share movement) Feb 14 (Reuters) - Jordan's Hikma Pharmaceuticals Plc said it expects a 23 percent growth in full-year revenue, up from its prior forecast of about 20 percent, benefiting from a strong performance in its injectables and generics businesses towards the end of 2013. The London-listed company, which has grown over the past year on the back of a shortage of doxycycline in the United States, also raised its full-year generics revenue forecast to $270 million, as sales of the antibiotic continued to rise. Shares in Hikma rose as much as 6.7 percent in early trade, making the stock the biggest percentage gainer on the FTSE-250 Midcap index < .FTMC>. The drugmaker has already raised its 2013 revenue forecast three times and said in November that it expected revenue from its generics unit to be about $260 million. [ID:nL3N0IK52Z] The U.S. Food and Drug Administration had said that there was a scarcity of doxycycline in the United States due to domestic manufacturing issues, adding that an acute shortage of substitutes was driving demand for the antibiotic. (http://link.reuters.com/rep52v) Doxycyline is used to treat bacterial infections such as urinary tract infections, acne, gonorrhea, and chlamydia as well as the tick-borne illness Lyme disease. The drug is also used to prevent malaria. The antibiotic was taken off the shortage list last October with no supply issues anticipated, according to the U.S. FDA website. (http://link.reuters.com/cej86v) Hikma said that it expects revenue from its generics business to be lower in 2014 due to increased competition in the U.S. doxycycline market. "A key issue is how long the doxycycline opportunity will last and how Hikma intends to guide the market in 2014, but we expect strong underlying growth," Jefferies analyst James Vane-Tempest wrote in a note. He added that an increase in pricing pressure in doxycycline would erode the company's current supernormal profitability. The company, which was founded in Amman in 1978, said its global injectables business performed well, with revenue growth of about 14 percent. "We are confident that our injectables business will continue to deliver strong revenue growth and an adjusted operating margin above 30 percent in 2014," the company said in a statement. [ID:nRSN0669Aa] Hikma's pretax profit nearly doubled to $111.6 million in the first-half. Revenue increased 20 percent to $638.3 million, boosted by a 137 percent revenue growth in the generics business. [ID:nL4N0GM14L] The company said earlier this week that Chief Executive Said Darwazah would also be appointed chairman, succeeding his father Samih Darwazah. [ID:nWLB0074M] Hikma shares were trading up 6 percent at 1320 at 0921 GMT on Friday on the London Stock Exchange. The stock has nearly doubled in value over the past year. (Reporting by Abhirup Roy and Roshni Menon in Bangalore; Editing by Supriya Kurane) ((abhirup.roy@thomsonreuters.com)(within UK +44 20 7542 1810, outside UK +91 80 6749 6126)(Reuters Messaging: abhirup.roy.thomsonreuters.com@reuters.net)) Keywords: HIKMA RESULTS/

BROKER UPDATE.........

RESEARCH ALERT-Hikma: Panmure raises target price

14 Feb 2014 - 08:49
Feb 14 (Reuters) - Hikma Pharmaceuticals PLC : * Panmure raises target price to 1375p from 1350p; rating buy For a summary of rating actions and price target changes on European companies: Reuters Eikon users, click on [RCH/EUROPE] Reuters 3000Xtra users, double-click [RCH/EUROPE] Reuters Station users, click .1580 ((nyc.equities.newsroom@reuters.com); (Reuters Messaging: saqib.ahmed.thomsonreuters.com@reuters.net) ((Bangalore Newsroom +91 80 6749 1130; within U.S. +1 646 223 8780))